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summarize indications for the use of different imaging techniques in patients with diag-
nosed or suspected coronary artery disease according to the current ESC practice guidelines.
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.Introduction
Contemporary patient management in cardiology stands on
two pillars: imaging and interventions. The current issue of Cor
et Vasa addresses the use of different imaging techniques in
patients with diagnosed or suspected coronary artery disease.
Our aim is to present a ‘‘horizontal’’ view of the topic in
different clinical settings, rather than viewing it by the
imaging modalities. The European Society of Cardiology
(ESC) delivers practice guidelines endorsed by many member* Corresponding author at: 3rd Department of Cardiology, School of Me
40-635 Katowice, Poland. Tel.: +48 32 252 3930; fax: +48 32 252 3930.
http://dx.doi.org/10.1016/j.crvasa.2015.10.006
0010-8650/# 2015 The Czech Society of Cardiology. Published by ElseNational Societies. This paper will be based on recommenda-
tions from the four ESC ofﬁcial documents, related to stable
CAD [1], acute coronary syndromes [2,3], and myocardial
revascularization [4].
Stable coronary artery disease [1]
In patients with stable CAD, cardiac imaging is pivotal
at several management stages, including establishment of
the diagnosis, identiﬁcation of associated conditions, riskdicine in Katowice, Medical University of Silesia, Ziolowa Street 47,
vier Sp. z o.o. All rights reserved..
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 4 0 5 – e 4 0 7e406stratiﬁcation, facilitation of the choice of treatment, and
evaluation of treatment effect.
Diagnosis of stable CAD is based on the Bayesian approach.
As the initial step, the pre-test probability of the disease is
estimated, derived from patient's age, sex, and chest pain
characteristics. Further testing strategy, including different
kinds of imaging, depends on the pre-test probability of
CAD. In general, in patients categorized as having low (<15%)
likelihood of ischemia, no additional non-invasive testing is
advocated. It has to be kept in mind, however, that in this
group there is a small proportion of subjects who actually do
have ischemia. Some patients, especially those with a
positive family history of premature CAD, concomitant
diabetes or renal dysfunction, may beneﬁt from further
testing.
Patients with high pre-test likelihood of ischemia (>85%)
may be diagnosed as having CAD and offered medical
treatment. Patients with stable symptoms and an intermedi-
ate (15–85%) probability of signiﬁcant disease are clearly
candidates for non-invasive testing.
After the diagnosis of CAD has been made, and optimal
medical therapy instituted, as the third step of the
diagnostic algorithm, based on the results on non-invasive
testing and symptoms, patients who could potentially
beneﬁt from revascularization should be selected for the
invasive testing.
At the initial presentation, all patients should have a
resting transthoracic echocardiography (TTE) performed (class
I, level of evidence B). It enables exclusion of other causes of
chest pain, identiﬁcation of wall motion abnormalities
suggestive of CAD, and evaluation of left ventricular (LV)
function which bears prognostic information. Cardiac mag-
netic resonance (CMR) may be used as an alternative imaging
method to detect structural changes and assess LV function in
patients with inconclusive TTE results and no contraindica-
tions to CMR.
The guidelines also state that carotid ultrasound should be
considered at this stage (class IIa, level of evidence C) to detect
increased intima-media thickness or plaque.
Further non-invasive testing depends on the likelihood of
the disease, test availability, and center experience. Patient's
ability to perform the test should always be taken into
consideration. As mentioned, in patients with the intermedi-
ate likelihood of CAD (15–85%), non-invasive testing to
conﬁrm or rule-out CAD is of special importance. In this
entire group, stress imaging is preferred to the ECG exercise
testing, but the imaging methods are especially valuable in
subjects in the high-intermediate range (66–85% likelihood of
CAD or LV EF < 50% without typical angina; class I, level of
evidence B), and in those in whom resting ECG abnormalities
do not allow to reliably interpret the exercise-induced
changes (class I, level of evidence B). Stress echocardiography,
CMR, and radionuclide methods (mostly single-photon
emission computed tomography [SPECT], but also positron
emission tomography [PET]), are potentially useful to prove or
disprove the presence of ischemia. If the ﬁrst imaging test (or
the ECG stress test) is not diagnostic, then another imaging
test should be performed. Exercise stress is deemed superior
to pharmacologic testing when possible (class I, level of
evidence C).CT angiography, which has a very high negative predictive
value, is most useful to rule-out rather than to conﬁrm the
diagnosis of CAD.
Hybrid techniques, combining SPECT/CT, PET/CT and PET/
CMR are now available at a few specialized centers. These
techniques combine the anatomical with functional coronary
assessment or provide more objective pathophysiological
data. Their role is likely to increase in the future.
It is important to note that imaging also plays an important
part in patients with the established stable CAD diagnosis. An
imaging stress test should be considered in symptomatic
patients with prior revascularization, and in those with
intermediate lesions on coronary arteriography (both class
IIa, level of evidence B).
Acute coronary syndromes
Patients presenting with ST-segment elevation (STEMI) [2]
Two different time points must be taken into consideration in
this clinical setting: at hospital presentation and after the
acute phase – preferably before discharge.
At presentation, patients with STEMI should be directed to
the invasive coronary angiography and subsequent primary
PCI with no delay (class I, level of evidence A). Echocardiogra-
phy may assist in making the diagnosis in uncertain cases, but
should not delay transfer for angiography (class IIB, level of
evidence C).
After the acute phase, all patients should have a transtho-
racic echocardiogram performed to assess the infarct size and
resting left ventricular function (class I, level of evidence B). If
echocardiography is not feasible, CMR may be used as an
alternative (class IIB, level of evidence C).
In patients with multivessel CAD in whom revasculariza-
tion of other vessels is considered, stress testing or imaging,
e.g. using stress perfusion scintigraphy, stress echocardiogra-
phy, PET or CMR, are indicated for evaluation of residual
ischemia and myocardial viability (class I, level of evidence A).
According to the guidelines, CT angiography has no role in
the routine management of STEMI patients (class III, level of
evidence C).
Patients presenting without persistent ST-segment elevation
(NST-ACS) [3]
In the ‘‘rule-in’’ and ‘‘rule-out’’ algorithm for the NST-ACS, the
guidelines rely on the biochemical markers only. It needs to be
emphasized however that coronary artery calcium (CAC)
evaluation by CT, especially in patients older than 45 years,
can be useful in this setting to rule-out the ACS. In these
circumstances there is no need for quantiﬁcation, and
therefore, the test can be performed even in patients with
arrhythmia, without the ECG gating. If no calcium is present,
the diagnosis of an ACS is unlikely, and another etiology for the
symptoms needs to be searched for.
If there is a high suspicion of NSTE-ACS, coronary
angiography should be performed, while in those with low
to intermediate CAD likelihood, CT angiography should be
considered.
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should be performed in all patients. It is useful to identify
abnormalities suggestive of myocardial ischemia or necrosis
(segmental hypo- or akinesia). Contrast echocardiography
and/or strain/strain rate imaging might improve the diagnos-
tic and prognostic value of the conventional echo assessment.
Echocardiography may be also useful in identiﬁcation of the
alternative diagnoses, and in diagnosing the patients with
hemodynamic instability of suspected cardiac origin.
At the time of hospital discharge, echocardiography, as well
as other imaging techniques, can provide important prognos-
tic information.
As pertains to the ofﬁcial ESC recommendations:
1. In patients with no recurrence of chest pain, normal ECG
and normal cardiac troponin levels, but suspected ACS, a
non-invasive stress test (preferably with imaging) for
inducible ischemia is recommended before deciding on
an invasive strategy (class I, level of evidence A).
2. Echocardiography is recommended to evaluate regional
and global LV function and to rule out differential diagnoses
(class I, level of evidence C).
3. CT coronary angiography should be considered as an
alternative to invasive angiography to exclude ACS if there
is a low or intermediate likelihood of CAD, and when cardiac
troponin values and/or ECG ﬁndings are not conclusive
(class IIa, level of evidence A).
Myocardial revascularization [4]
In the candidates for myocardial revascularization, non-
invasive imaging is used to conﬁrm the presence of ischemia,
assess the area of ischemia, and detect myocardial viability.
The use of non-invasive test depends on clinical presenta-
tion of CAD. This has been more speciﬁcally addressed in
previous paragraphs of this paper. Notably, conﬁrmation of the
presence of ischemia is required in patients with suspected or
known CAD in the non-acute setting. In patients with the
intermediate (15–85%) pre-test probability of CAD, imaging
tests, such as stress echo, nuclear imaging, stress CMR or PET
perfusion (all class I, level of evidence A), should be done, and
are preferred over the ECG stress testing. In those with a high
(>85%) probability of signiﬁcant CAD, a straight advancement
to the invasive coronary angiography is advocated (class I,
level of evidence A).
As the presence of a large area of ischemia, exceeding 10%
of the left ventricular mass, is associated with prognostic
improvement with revascularization (class I, level of evidence
B), it should be assessed in patients, in whom revasculariza-
tion for symptomatic improvement alone is questionable.Radionuclide methods, especially SPECT, as well as CMR, are
best suitable here, but stress echo is also acceptable.
With the exception of patients with STEMI in whom the
echocardiographic examination might delay PCI, all revascu-
larization candidates should have the LV function assessed by
echocardiography. In those with poor LV function, myocardial
viability should be assessed using stress echo, radionuclide
imaging and/or CMR in order to establish the optimal
treatment strategy.
Obviously, invasive coronary angiography has to be
performed in all patients in whom the need for myocardial
revascularization is considered. Again, the clinical setting is
important here. Patients with ACS generally require an acute
intervention (most commonly PCI). Also in stable symptom-
atic patients with high (>85%) probability of signiﬁcant CAD,
an invasive angiography with no previous noninvasive
testing is advocated, if revascularization is considered.
Otherwise, noninvasive functional tests are indicated as
described above.
The results of invasive angiography enable calculation of
the SYNTAX score [5], which should be used to choose the
optimal revascularization strategy (PCI vs CABG) in patients
with the left main and three-vessel disease.
Further tests, such as IVUS, optical coherent tomography
(OCT) and FFR, performed at the time of invasive coronary
angiography, are clinically useful in establishing lesion severity
and its functional signiﬁcance, providing better guidance on the
need for and strategy of the revascularization procedure. IVUS
and OCT also play a role in the assessment of the immediate PCI
result.
r e f e r e n c e s
[1] G. Montalescot, U. Sechtem, S. Achenbach, et al., ESC
guidelines on the management of stable coronary artery
disease, European Heart Journal 34 (2013) 2949–3003.
[2] P.G. Steg, S.K. James, D. Atar, et al., ESC guidelines for the
management of acute myocardial infarction in patients
presenting with ST-segment elevation, European Heart
Journal 33 (2012) 2569–2619.
[3] M. Rofﬁ, C. Patrono, J.P. Collet, et al., ESC guidelines for the
management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation,
European Heart Journal (2015), http://dx.doi.org/10.1093/
eurheartj/ehv320.
[4] S. Windecker, P. Kolh, F. Alfonso, et al., 2014 ESC/EACTS
guidelines on myocardial revascularization, European Heart
Journal 35 (2014) 2541–2619.
[5] P.W. Serruys, M.C. Morice, A.P. Kappetein, et al.,
Percutaneous coronary intervention versus coronary-artery
bypass grafting for severe coronary artery disease, New
England Journal of Medicine 360 (2009) 961–972.
